Chiltern Appoints Dr. Michael Wisniewski As Senior Executive Director, Biometrics

LONDON, and WILMINGTON, N.C., May 28, 2014 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), today announced the appointment of Michael Wisniewski, PhD as Sr. Executive Director, Biometrics to lead Chiltern's global Biostatistics team and provide expertise and consultancy to Chiltern clients.

Alecia Barbee, Chiltern's Vice President, Global Biometrics offered: "We are very excited to have Dr. Wisniewski join Chiltern to oversee our global Biostatistics and Statistical Programming groups. Michael brings an outstanding mix of Pharma, CRO, and academia experiences that will help Chiltern continue to advance our industry-leading biometrics service offerings."

With 30 years industry experience, Dr. Wisniewski joins Chiltern as a leader in product development, including over 23 years at Glaxo SmithKline as Executive Director of Clinical Statistics and Programming.  He is widely published in oncology and respiratory topics and has been involved in 11 regulatory submissions to FDA and other agencies leading to marketing approval.

Company profile

About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Global Clinical Development, Global Scientific Services, and Global Resourcing Solutions. Chiltern prides itself as a development partner that offers innovation, responsiveness and quality delivery.

Further information is available at: www.chiltern.com.

For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
2528 Independence Blvd. Suite 101
Wilmington, NC 28412
USA
Tel:  +1 (910) 338 4760
Email: global.marketing@chiltern.com

SOURCE Chiltern

RELATED LINKS
http://www.chiltern.com

reade more... Résuméabuiyad

MedNet Appoints Clareece West As Chief Operating Officer

MINNETONKA, Minn., July 23, 2014 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that M. Clareece West, a proven life sciences industry executive with over 25 years of experience, has been named Chief Operating Officer (COO).  Clareece will be responsible for MedNet's day-to-day operating activities, driving revenue and sales growth, operational efficiency and quality product/service delivery. 

"We welcome Clareece, who brings an exceptional track record in operations, executive management and global business development," noted John M. (Rob) Robertson, President and CEO of MedNet Solutions.  "With Arrowroot Capital's recent investment in our company, and the very positive reception that iMedNet™ EDC is receiving from both the sponsor and CRO communities, she is joining MedNet at an incredibly exciting time.  The future is very bright for our company, and I'm thrilled to have Clareece join our executive team as we work to take MedNet to the next level."

"MedNet's growth strategy and quality eClinical technology platforms combined with their impeccable industry reputation make this an exciting opportunity," remarked Clareece West.  "Their established footprint within the device and pharma communities, along with their continued focus on serving the technology needs of both CROs and sponsors, align perfectly with our industry's craving for better and more efficient technologies to help offset expensive service costs."

Prior to joining MedNet, Clareece held senior leadership positions with global Clinical Research Organizations (CROs).  Clareece brings significant M&A experience and extensive international business expertise that will be valuable for MedNet's continued global expansion. 

Stay in touch with MedNet:

About MedNet Solutions

MedNet Solutions is a leading healthcare technology company specializing in electronic data solutions designed for the global life sciences community.  MedNet's proven, flexible and easy-to-use cloud-based eClinical systems dramatically improve the efficiency of clinical studies and registries of all types and sizes.  Beyond simply electronic data capture (EDC), MedNet's solutions deliver the tools and dashboards required to expertly manage all aspects of clinical research.  Since 2001, pharmaceutical, medical device, biotechnology and Contract Research Organizations (CROs) around the world have trusted MedNet to consistently deliver the technology innovation, experience and reliability they need for success.  For more information, please visit www.mednetstudy.com.

Contact Information:
Dirk H. Nelson
Director of Marketing
110 Cheshire Lane, Suite 300
Minnetonka, MN 55305
USA
(763) 258-2735

SOURCE MedNet Solutions

RELATED LINKS
http://www.mednetstudy.com

reade more... Résuméabuiyad

FST21 Appoints Arie Melamed As Chief Marketing Officer

NEW YORK, March 27, 2014 /PRNewswire/ -- FST21, the leading biometric access solution provider, today announces the addition of Arie Melamed to the company's C-level staff as Chief Marketing Officer.

Mr. Melamed brings with him over 20 years of experience in sales and marketing, most recently having served as Head of Global Marketing & Channel Sales for ECI Telecom, a global telecommunication networking provider.    

"It's an honor to join FST21, a company on the cutting edge of biometric access control technology," says Mr. Melamed. "Biometric access control is a hot topic for both the national and international security markets, and I am thrilled to utilize my experience and knowledge to lead the company's marketing forward."

At ECI Telecom, Mr. Melamed managed a global marketing and channel team. His vast knowledge of sales and marketing tactics helped him lead an increase in the company's indirect sales and implement a series of progressive revenue marketing procedures.

"Arie has a proven record of change management with high-profile technology companies. I am confident that his past experience overseeing global marketing for a major telecommunications company will allow him to manage our international marketing ventures effortlessly," says Major-General Aharon Zeevi Farkash, Founder and CEO, FST21. "The team is excited to have him in the company, and we all look forward to the expansion of FST21's business over the next year." 

Previously to ECI, Mr. Melamed also spent several years as the Associate Vice President of Sales for Enavis Networks. Mr. Melamed earned a degree in Applied Physics and Electro-Optics from the Jerusalem College of Technology, as well as an MBA from Ben Gurion University in Israel.

FST21 has recently announced growth plans for the future, including its continued expansion into the U.S. market with the opening of an office at 7 World Trade Center in New York City. 

ABOUT FST21:
FST21 is a leading biometric access control solutions provider. FST21's SafeRise provides top security and convenience by fusion of real time information for fast and automatic access control. It's hassle-free and allows authorized users quick and convenient access. SafeRise's In Motion Identification™ uses a fusion of biometric and analytic technologies that include facial recognition, behavior analysis and voice recognition.

SOURCE FST21

RELATED LINKS
http://www.fst21.com

reade more... Résuméabuiyad